Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that KIT p.D816V status confers therapeutic sensitivity to Imatinib in patients with Aggressive Systemic Mastocytosis.
This statement is based on a regulatory approval from the Health Canada:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.